Recently, there has been rumors that
the Dengvaxia formulated by Sanofi Pasteur will soon be recalled due to the
discovery on its adverse effects to the patients vaccinated with it that have
not yet contacted Dengue firsthand. A Public Health expert also a former DOH( Department of Health) Undersecretary, by Dr. Susan Pineda –
Mercado have spoken on a very recent
interview that they had earlier advised the
DOH (Dept. of Health) to refrain from implementing the use of Dengvaxia
although Sanofi Pasteur reps has reiterated that the country’s BFAD has
approved of it way back in 2014. Also in an International Public Health
Magazine published in 2015 – the general public has also been warned that on
the first two years of vaccination, it can immunize individuals who have not
had Dengue before BUT will soon suffer from severe Dengue infection after the
two-year grace period, allegedly.
